Oluchi C. Oke, MD
Department of General Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of General Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, The Woodlands, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, The Woodlands, TX
Education & Training
Degree-Granting Education
| 2013 | University of Illinois College of Medicine, Peoria, IL, USA, MD, Doctor of Medicine |
| 2008 | Northwestern University, Evanston, IL, USA, BS, Communication Sciences & Disorders (Mj), African History (Mn) |
Postgraduate Training
| 2016-2019 | Hematology/Oncology Fellow, Hematology, University of Texas MD Anderson Cancer Center, Houston |
| 2013-2016 | Internal Medicine Residency, Vanderbilt University, Nashville, TN |
Board Certifications
| 2019 | Hematology |
| 2019 | Oncology |
| 2016 | Internal Medicine |
Experience & Service
Academic Appointments
Nocturnist, University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - Present
Honors & Awards
| 2015 | Resident Travel Award, Conquer Cancer Foundation of American Society of Clinical Oncology |
| 2012 | The Doctor's Doctor, Merk Manual Award |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Lang JJ, Issa R, Lombardi C, Garcia E, Oke OC, Ekwenna O. Trends in Race and Ethnicity Among Matriculants to US Oncology Training Programs, 2015-2020. JAMA Netw Open 4(10):e2128530, 2021. e-Pub 2021. PMID: 34618042.
- Oke O, Ranasinghe W, Tang C, Shaaban S, Xiao L, Reichard CA, Anscher MS, Chapin BF, Aparicio A. Impact of Definitive Local Therapy in Men with Primary Small Cell Prostate Carcinoma. Eur Urol 80(3):389-390, 2021. e-Pub 2021. PMID: 33824032.
- Parkes A, Warneke CL, Clifton K, Al-Awadhi A, Oke O, Pestana RC, Alhalabi O, Litton JK, Hortobagyi GN. Prognostic Factors in Patients with Metastatic Breast Cancer. Oncologist 11(23):1282-88, 2018. e-Pub 2018. PMID: 30120166.
- Parkes A, Clifton K, Al-Awadhi A, Oke O, Warneke CL, Litton JK, Hortobagyi GN. Characterization of Bone Only Metastasis Patients with Respect to Tumor Subtypes. NPJ Breast Cancer 4(2):1-7, 2018. e-Pub 2018. PMID: 29387785.
- Ukaegbu O, Sethi T, Goodman S, Rubinstein SM, Hung R, Jagasia MH, Kassim AA, Lacy S, Langone A, Lenihan D, Savani BN, Slosky D, Cornell RF. Autologous Hematopoietic Cell Transplant (AHCT) Offers Prolonged Progression Free and Overall Survival in Patients with Light Chain Amyloidosis (AL) Compared with Chemotherapy Alone. Biology of Blood and Marrow Transplant 33(3):S233–S234, 2016.
- Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring J M, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG,Hanif A, Champlin R, Hari P, Gupta V. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biology of Blood and Marrow Transplant 22(3):432–440, 2016.
- Ukaegbu OC, Caldwell ME, Reddy NM. Concurrent B-cell Follicular and Refractory CD30+ Large Cell Transformation of Mycosis Fungoides Responsive to Rituximab and Brentuximab Vedotin. Journal of Blood Disorders & Transfusion 6(2):1000259, 2015.
- Oke O, Niu J, Chavez-MacGregor M, Zhao H, Giordano SH. Adjuvant Tamoxifen Adherence in Men with Early-stage Breast Cancer. Cancer. e-Pub 2021. PMID: 34597415.
Abstracts
- Jambunathan S, Lang J, Mays M, Oke O. Sociodemographic Trends in COVID-19 Mortality in Patients with Cancer: A Nationwide Analysis. Journal of Clinical Oncology, 2022.
- Oke O, Niu J, Chavez-MacGregor M, Zhao H, Giordano SH. Adjuvant Tamoxifen Adherence in Men with Early Breast Cancer. Journal of Clinical Oncology 36(15):550-550, 2018.
- Oke O, Tang C, Chapin B, Aparicio A. Impact of Definitive Local Therapy (LT) in Men with Primary Small Cell (or poorly differentiated neuroendocrine) Prostate Carcinomas (pSCPC). Journal of Clinical Oncology, 2018.
- Oke O, Warneke CL, Chavez-Mac Gregor M, Milbourne A, Litton JK. Outcomes Related to Delayed Initiation of Anti-HER 2 Therapy in Pregnant HER2 Positive Breast Cancer Patients. Journal of Clinical Oncology 35(15), 2017.
- Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring J M, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG,Hanif A, Champlin R, Hari P, Gupta V. Autologous Hematopoietic Cell Transplant Offers Prolonged Progression Free and Overall Survival in Patients with Light Chain Amyloidosis Compared with Chemotherapy Alone. Biol Blood Marrow Transplant 22(3):S233-S234, 2016.
- Decker I, Ukaegbu OC, Goodman SA, Lenihan DJ, Hung RR, Kassim AA, Harrell SL, McDonagh K, Phillips SE, Rawling KT, Rubinstein SM, Sethi TK, Cornell RF. Six-Minute Walk Test as a Measure of Functional Change after Chemotherapy in Cardiac AL Amyloidosis. American Society of Hematology 126(23):1841, 2015.
- Hill L, Ukaegbu OC, Savani BN, Sengsayadeth S, Goodman S, Brandt SJ, Chinratanalab W. Impact of Different Mobilization Methods on Graft Composition and Outcome after Autologous Stem Cell Transplantation: Implications for Upfront Use of Plerixafor. American Society of Hematology 124(21):1125, 2014.